Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway

被引:75
作者
Drosopoulos, KG
Roberts, ML
Cermak, L
Sasazuki, T
Shirasawa, S
Andera, L
Pintzas, A
机构
[1] Natl Hellen Res Fdn, Lab Signal Mediated Gene Express, Inst Biol Res & Biotechnol, Athens 11635, Greece
[2] Acad Sci Czech Republ, Inst Mol Genet, Lab Cell Signaling Apoptosis, CZ-14220 Prague, Czech Republic
[3] Int Med Ctr Japan, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan
[4] Univ Patras, Dept Pharm, Rion 26500, Greece
关键词
D O I
10.1074/jbc.M412483200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
RAS oncogenes play a major role in cancer development by activating an array of signaling pathways, most notably mitogen-activated protein kinases, resulting in aberrant proliferation and inhibition of apoptotic signaling cascades, rendering transformed cells resistant to extrinsic death stimuli. However, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is able to kill specific tumor cells through the engagement of its receptors, death receptor 4 (DR4) and death receptor 5 (DR5), and the activation of apoptotic pathways, providing promising targets for anticancer therapies. In this study, we show that TRAIL induces cell death in human colon adenocarcinoma cells in a MEK-dependent manner. We also report a prolonged MEK-dependent activation of ERK1/2 and increased c-FOS expression induced by TRAIL in this system. Our study reveals that transformation of the colon cell line Caco-2 by Ki- and mainly by Ha-ras oncogenes sensitizes these cells to TRAIL-induced apoptosis by causing specific MEK-dependent up-regulation of DR4 and DR5. These observations taken together reveal that RAS-MEK-ERK1/2 signaling pathway can sensitize cells to TRAIL-induced apoptosis by up-regulating DR4 and DR5 and overall imply that TRAIL-based therapeutic strategies using TRAIL agonists could be used in cases of human colon cancers bearing RAS mutations.
引用
收藏
页码:22856 / 22867
页数:12
相关论文
共 43 条
[31]   ALTERED GROWTH OF HUMAN COLON CANCER CELL-LINES DISRUPTED AT ACTIVATED KI-RAS [J].
SHIRASAWA, S ;
FURUSE, M ;
YOKOYAMA, N ;
SASAZUKI, T .
SCIENCE, 1993, 260 (5104) :85-88
[32]   Fas-associated death domain protein (FADD) and caspase-8 mediate up-regulation of c-Fos by Fas ligand and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) via a FLICE inhibitory protein (FLIP)-regulated pathway [J].
Siegmund, D ;
Mauri, D ;
Peters, N ;
Juo, P ;
Thome, M ;
Reichwein, M ;
Blenis, J ;
Scheurich, P ;
Tschopp, J ;
Wajant, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (35) :32585-32590
[33]   Pro-caspase-3 is a major physiologic target of caspase-8 [J].
Stennicke, HR ;
Jurgensmeier, JM ;
Shin, H ;
Deveraux, Q ;
Wolf, BB ;
Yang, XH ;
Zhou, Q ;
Ellerby, HM ;
Ellerby, LM ;
Bredesen, D ;
Green, DR ;
Reed, JC ;
Froelich, CJ ;
Salvesen, GS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (42) :27084-27090
[34]   Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development [J].
Takeda, K ;
Smyth, MJ ;
Cretney, E ;
Hayakawa, Y ;
Kayagaki, N ;
Yagita, H ;
Okumura, K .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 195 (02) :161-169
[35]  
TOLCHER AW, 2004, J CLIN ONCOL S, V22
[36]   MAPK/ERK overrides the apoptotic signaling from Fas, TNF, and TRAIL receptors [J].
Tran, SEF ;
Holmström, TH ;
Ahonen, M ;
Kähäri, VM ;
Eriksson, JE .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (19) :16484-16490
[37]   ERK-MAPK signaling coordinately regulates activity of Rac1 and RhoA for tumor cell motility [J].
Vial, E ;
Sahai, E ;
Marshall, CJ .
CANCER CELL, 2003, 4 (01) :67-79
[38]   THE MULTISTEP NATURE OF CANCER [J].
VOGELSTEIN, B ;
KINZLER, KW .
TRENDS IN GENETICS, 1993, 9 (04) :138-141
[39]   TNF-related apoptosis inducing ligand (TRAIL) and its receptors in tumor surveillance and cancer therapy [J].
Wajant, H ;
Pfizenmaier, K ;
Scheurich, P .
APOPTOSIS, 2002, 7 (05) :449-459
[40]   Tumoricidal activity of tumor necrosis factor related apoptosis-inducing ligand in vivo [J].
Walczak, H ;
Miller, RE ;
Ariail, K ;
Gliniak, B ;
Griffith, TS ;
Kubin, M ;
Chin, W ;
Jones, J ;
Woodward, A ;
Le, T ;
Smith, C ;
Smolak, P ;
Goodwin, RG ;
Rauch, CT ;
Schuh, JCL ;
Lynch, DH .
NATURE MEDICINE, 1999, 5 (02) :157-163